When LGG patients were classified into three groups according to the guideline of the 2016 WHO classification of CNS tumors, patients with IDH1 mutations and 1p19q codeletion had the best OS (median survival: 6.879 years; five-year survival rate: 77.3%; adjusted HR = 0.221), but those with wild-type IDH1 had the worst OS (median survival: 2.003 years; five-year survival rate: 34.1%) (Figure 4G). Here, IDH1 is linked to central nervous system neoplasm.